CN116059124A - Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof - Google Patents
Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN116059124A CN116059124A CN202310205916.XA CN202310205916A CN116059124A CN 116059124 A CN116059124 A CN 116059124A CN 202310205916 A CN202310205916 A CN 202310205916A CN 116059124 A CN116059124 A CN 116059124A
- Authority
- CN
- China
- Prior art keywords
- gamma
- aminobutyric acid
- composition
- liquid crystal
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 127
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 63
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000007794 irritation Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 62
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000004519 grease Substances 0.000 claims abstract description 7
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 235000019198 oils Nutrition 0.000 claims description 20
- -1 arachidyl alcohol glucoside Chemical class 0.000 claims description 16
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 12
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229960000735 docosanol Drugs 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000000265 homogenisation Methods 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- 150000002191 fatty alcohols Chemical class 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 229940104261 taurate Drugs 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 6
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 6
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 2
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241000218993 Begonia Species 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229940047670 sodium acrylate Drugs 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 abstract description 21
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 9
- 230000000638 stimulation Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 16
- 239000012071 phase Substances 0.000 description 13
- 230000037303 wrinkles Effects 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The application provides a composition for improving the irritation of gamma-aminobutyric acid, a preparation method and application thereof, and relates to the technical field of cosmetic skin care products. The composition comprises gamma-aminobutyric acid and a liquid crystal emulsifier, wherein the liquid crystal emulsifier has an amphiphilic molecular end, the liquid crystal emulsifier dissolves grease, so that the grease is mixed to form liquid crystal oil-in-liquid gel, and then water is added into the gel to obtain liquid crystal emulsion. The liquid crystal can slow down the release speed of the active ingredients dissolved in the oil phase, and reduce the transmission speed of the active ingredients dissolved in the oil drop between interfaces, thus prolonging the activity of the active ingredients, controlling the direct contact of the substances and the skin, reducing the stimulation of the active ingredients with high concentration to the skin, slowing down the side effect of gamma-aminobutyric acid when in use, namely obviously improving and reducing the adverse reaction of the gamma-aminobutyric acid to the skin, and overcoming the stimulation of the emulsion system cosmetic containing high addition amount of the gamma-aminobutyric acid to the skin.
Description
Technical Field
The application relates to the technical field of cosmetic skin care products, in particular to a composition for improving the irritation of gamma-aminobutyric acid, a preparation method and application thereof.
Background
Gamma-aminobutyric acid (GABA), also known as aminobutyric acid, 4-aminobutyric acid, piperidine acid, with molecular formula C 4 H 9 NO 2 The molecular weight is 103.1, is a non-protein amino acid widely distributed in animals and plants, and plays an irreplaceable role in regulating the vital activity of organisms. Gamma-aminobutyric acid is an inhibitory neurotransmitter of the mammalian central nervous system, widely distributed in prokaryotes and eukaryotes, and has been demonstrated to have effects of relieving anxiety, lowering blood pressure, improving sleep, removing wrinkles and whitening. When removing wrinkles, the gamma-aminobutyric acid can relax the tight muscle nerve tissue, quickly penetrate the skin, lighten fine wrinkles, strengthen the relaxation function of the muscle and play a role in quickly removing wrinkles.
By utilizing the property of the gamma-aminobutyric acid, a series of products such as facial masks, face creams, eye creams and the like are developed in the prior art for use in the wrinkle removal field, but the gamma-aminobutyric acid has certain side effects, namely, discomfort symptoms such as stinging, tingling, itching, burning and the like can be generated when the gamma-aminobutyric acid with high concentration is contacted with skin, and the side effects have positive correlation with the concentration. Currently, the content of gamma-aminobutyric acid in cosmetics is recommended to be at most 6.0%. Under the limit of the side effect of the gamma-aminobutyric acid, the product cannot reach the expected wrinkle-removing concentration, which limits the wrinkle-removing effect of the gamma-aminobutyric acid and the wide application of the gamma-aminobutyric acid in the wrinkle-removing field to a certain extent.
Disclosure of Invention
The invention aims to provide a composition for improving the irritation of gamma-aminobutyric acid, a preparation method and application thereof, and aims to solve the problems that the existing gamma-aminobutyric acid has uncomfortable symptoms such as stink, tingling, itching, burning and the like when contacting with skin at high concentration, so that the product cannot reach the expected wrinkle removal concentration, and the wrinkle removal effect and application of the gamma-aminobutyric acid are limited.
To achieve the above object, the present application provides a composition for improving the irritation of gamma-aminobutyric acid, comprising, per 100 parts by weight: 1-6 parts of gamma-aminobutyric acid and 1-4 parts of liquid crystal emulsifier, wherein the liquid crystal emulsifier comprises the following components in parts by weight: arachidyl alcohol, behenyl alcohol and arachidyl alcohol glucoside, wherein the weight ratio of the arachidyl alcohol to the behenyl alcohol to the arachidyl alcohol glucoside is (50-60): (25-35): (10-20), the balance being water. Wherein, the gamma-aminobutyric acid can be 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5 or 6 parts; the liquid crystal emulsifier may be, for example, 1, 1.5, 2, 2.5, 3, 3.5 or 4 parts.
The liquid crystal emulsifier is an emulsifier capable of forming a liquid crystal structure and has an amphiphilic molecular end, and can be used for dissolving grease, mixing the grease to form liquid crystal oil-in-liquid gel, and then adding water into the gel to obtain the liquid crystal emulsion. The liquid crystal emulsifier needs to contain amphiphilic molecules capable of forming a liquid crystal structure, so that the liquid crystal emulsifier has the main characteristics that two groups with very different solubility properties are arranged in the same molecule, one end of the molecule is a hydrophilic polar group which can be mixed with water or other polar groups in any ratio, and the other end is a hydrophobic group or a lipophilic hydrocarbon chain which can be dissolved in most hydrocarbon or nonpolar solvents. There are roughly six types of liquid crystal emulsifiers: sucrose esters, egg phospholipids, glucosides, olives, phosphates, stearoyl groups.
The liquid crystal structure can improve the stability of the product in the skin care emulsion, has high-efficiency moisturizing effect, can slowly release active ingredients and provides excellent skin feel. This is because the liquid crystal phase obtained under certain conditions can be adsorbed on the oil-water interface to form a stable protective layer, so that the droplets can be prevented from agglomerating due to mutual collision. The adsorption layer formed by the liquid crystal can greatly reduce long-range van der Waals force between liquid drops, thereby playing a role in stabilization. In addition, the crystals formed increase viscosity as they form a network, all of which can increase the stability of the emulsion.
In the skin care product containing the liquid crystal structure, the water phase has a glue net structure, the layered liquid crystal phase exists around the oil drops, and the water is absorbed and swelled in the layered structure, so that when the product with the structure is smeared on the skin, the water cannot volatilize immediately, and the effect of lasting filling of the skin with the water can be achieved.
The liquid crystal slows the release rate of the active ingredient dissolved in the oil phase, which is said to be 1000 times slower than without this structure. This is because the multi-layer structure of the liquid crystal can control the effect of the slow release of the active ingredient, reduce the transfer rate of the active ingredient dissolved in the oil droplets between interfaces, and thus prolong the activity of the active ingredient. Typically, the common type of oil-in-water emulsion is an oil/water structure, whereas oil-in-water emulsions employing liquid crystal emulsifiers are capable of forming unique oil/liquid crystal/water structures. When the liquid crystal structure is destroyed, the oil content in the liquid crystal structure is released.
The animal body and the human body have found the existence of liquid crystalline substances, and many phenomena in the organism are related to liquid crystals, such as cell membranes, spinal fluid, DNA, RNA and the like, all have the property of liquid crystals. The lipid bilayer of the keratinocyte gap is also a typical liquid crystal structure, and it is known from the principle of similar miscibility that cosmetics containing the liquid crystal structure can adsorb to the stratum corneum of the skin and promote permeation of active ingredients more than cosmetics of a common structure.
An outstanding advantage of oil-in-water emulsions with liquid crystalline structures over general emulsions is a fresh skin feel. The lamellar structure of the liquid crystal emulsion is similar to the phospholipid bilayer structure of the cell membrane of human skin cells, so that the liquid crystal emulsion can give people excellent skin feel experience, the initial skin feel is moist, and the liquid crystal emulsion is slightly cool after being spread for demulsification, fresh and not greasy.
Preferably, the composition further comprises, per 100 parts by weight: 5-10 parts of grease;
the oil is selected from isononyl isononanoate, glycerol tri (ethyl hexanoate), polydimethylsiloxane and Begonia seed oil.
Preferably, the grease is selected from any one or two of isononyl isononanoate and tri (ethylhexanoic acid) ester.
Preferably, the composition further comprises, per 100 parts by weight: 0.3 to 1 part of fatty alcohol and 0.5 to 2 parts of thickener;
the fatty alcohol is selected from any one or more of cetostearyl alcohol, cetyl alcohol, stearyl alcohol and behenyl alcohol;
the thickener is selected from one or more of xanthan gum, sodium polyacryl dimethyl taurate, sodium acrylate/sodium acryloyl dimethyl taurate copolymer, polyacrylate crosslinked polymer-6 and carbomer.
Preferably, the fatty alcohol is selected from cetostearyl alcohol or behenyl alcohol;
preferably, the thickener is selected from xanthan gum and sodium polyacryl dimethyl taurate.
Preferably, the composition further comprises, per 100 parts by weight: 3.5 to 12 parts of preservative and 1 to 3 parts of humectant;
the preservative comprises: any one or a combination of a plurality of 1, 3-butanediol, p-hydroxyacetophenone and 1, 2-hexanediol;
the moisturizer comprises: glycerol.
The present application also provides a method for preparing a composition for improving the irritation of gamma-aminobutyric acid, comprising:
mixing 1, 3-butanediol, glycerol, xanthan gum, p-hydroxyacetophenone and water, heating, dissolving, and maintaining the temperature to obtain a water phase;
mixing oil, a liquid crystal emulsifier and fatty alcohol, heating, dissolving and preserving heat to obtain an oil phase;
adding the oil phase into the water phase, adding sodium polyacryl dimethyl taurate, and emulsifying and homogenizing;
and after the emulsification and homogenization are finished, stirring and cooling, respectively adding 1, 2-hexanediol and gamma-aminobutyric acid, and uniformly stirring to obtain the composition for improving the irritation of the gamma-aminobutyric acid.
Preferably, the speed of the emulsification homogenization is 3600 to 4500rpm, for example, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400 or 4500rpm; the emulsifying and homogenizing time is 5-8 min, for example, can be 5, 6, 7 or 8min; the stirring and cooling speed is 260-300 rpm, and can be 260, 270, 280, 290 or 300rpm, for example.
The application also provides application of the composition for improving the gamma-aminobutyric acid irritation in preparing skin care products.
The application also provides a skin care product comprising the composition for improving the irritation of gamma-aminobutyric acid.
Compared with the prior art, the beneficial effects of this application include:
the composition for improving the gamma-aminobutyric acid stimulation comprises gamma-aminobutyric acid and a liquid crystal emulsifier, wherein the liquid crystal emulsifier is provided with an amphiphilic molecular end, one end of the liquid crystal emulsifier is a hydrophilic polar group and can be mixed with water or other polar groups in any ratio, and the other end of the liquid crystal emulsifier is a hydrophobic group or an oleophilic hydrocarbon chain and can be dissolved in most hydrocarbon or nonpolar solvents; the liquid crystal emulsifier dissolves the oil and fat into the gel to mix to form an oil-in-liquid crystal gel, and then water is added to the gel to obtain a liquid crystal emulsion. The liquid crystal can slow down the release speed of the active ingredients dissolved in the oil phase, and reduce the transmission speed of the active ingredients dissolved in the oil drop between interfaces, thus prolonging the activity of the active ingredients, controlling the direct contact of the substances and the skin, reducing the stimulation of the active ingredients with high concentration to the skin, slowing down the side effect of gamma-aminobutyric acid when in use, namely obviously improving and reducing the adverse reaction of the gamma-aminobutyric acid to the skin, and overcoming the stimulation of the emulsion system cosmetic containing high addition amount of the gamma-aminobutyric acid to the skin. And the skin care product containing the liquid crystal structure has excellent stability, high moisture retention and excellent skin feel.
Detailed Description
The term as used herein:
"prepared from … …" is synonymous with "comprising". The terms "comprising," "including," "having," "containing," or any other variation thereof, as used herein, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.
The conjunction "consisting of … …" excludes any unspecified element, step or component. If used in a claim, such phrase will cause the claim to be closed, such that it does not include materials other than those described, except for conventional impurities associated therewith. When the phrase "consisting of … …" appears in a clause of the claim body, rather than immediately following the subject, it is limited to only the elements described in that clause; other elements are not excluded from the stated claims as a whole.
When an equivalent, concentration, or other value or parameter is expressed as a range, preferred range, or a range bounded by a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. For example, when ranges of "1 to 5" are disclosed, the described ranges should be construed to include ranges of "1 to 4", "1 to 3", "1 to 2 and 4 to 5", "1 to 3 and 5", and the like. When a numerical range is described herein, unless otherwise indicated, the range is intended to include its endpoints and all integers and fractions within the range.
In these examples, the parts and percentages are by mass unless otherwise indicated.
"parts by mass" means a basic unit of measurement showing the mass ratio of a plurality of components, and 1 part may be any unit mass, for example, 1g may be expressed, 2.689g may be expressed, and the like. If we say that the mass part of the a component is a part and the mass part of the B component is B part, the ratio a of the mass of the a component to the mass of the B component is represented as: b. alternatively, the mass of the A component is aK, and the mass of the B component is bK (K is an arbitrary number and represents a multiple factor). It is not misunderstood that the sum of the parts by mass of all the components is not limited to 100 parts, unlike the parts by mass.
"and/or" is used to indicate that one or both of the illustrated cases may occur, e.g., a and/or B include (a and B) and (a or B).
Embodiments of the present application will be described in detail below with reference to specific examples, but it will be understood by those skilled in the art that the following examples are only for illustration of the present application and should not be construed as limiting the scope of the present application. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The components of the essence milk of example 1 include: 3 parts of isononyl isononanoate, 3 parts of glycerol tri (ethylhexanoate), 2 parts of a liquid crystal emulsifier, 0.6 part of behenyl alcohol, 80.7 parts of deionized water, 5 parts of 1, 3-butanediol, 2 parts of glycerol, 0.5 part of p-hydroxyacetophenone, 0.1 part of xanthan gum, 1.5 parts of gamma-aminobutyric acid, 1 part of sodium polyacryl dimethyl taurate and 0.6 part of 1, 2-hexanediol. Wherein the liquid crystal emulsifier is MONTANOV202 (INCI is arachidyl alcohol, behenyl alcohol, arachidyl alcohol glucoside is (50-60), 25-35, 10-20) purchased from SEPPIC company, france, and MONTANOV202 belongs to glucoside type liquid crystal emulsifier. The emulsifier is readily biodegradable, at least 60% biodegradable at 28 days; compared with other tested emulsifying agents, the emulsion can form an optimal dominant elastic network, thereby bringing excellent stability to the formula; meanwhile, the emulsifier has a moisturizing effect.
Taking a homogenizer, a sample of 400g of the essence emulsion as an example, the preparation method of the essence emulsion of the example 1 is described, comprising the following steps:
1. weighing
1.1 aqueous phase
(1) Weighing 20g of 1, 3-butanediol, 8g of glycerol and 0.4g of xanthan gum, adding into a beaker, and shaking the beaker to uniformly disperse the xanthan gum in the polyol;
(2) And weighing 322.8g of deionized water and 2g of p-hydroxyacetophenone, adding into the beaker, manually stirring until the xanthan gum is dissolved in water, and finally heating, dissolving and preserving heat for 30min in a water bath kettle at 85 ℃.
1.2 oil phase
(1) 12g isononyl isononanoate, 12g tri (ethyl hexanoate), 8g liquid crystal emulsifier and 2.4g behenyl alcohol are weighed in turn into another beaker and placed in a water bath kettle at 85 ℃ for heating, dissolving and heat preservation.
2. Emulsification process
(1) The homogenizing head is located in the middle lower part of the 500ml beaker. The whole emulsification process keeps the position basically motionless;
(2) Gradually adding the oil phase into the water phase for homogenization, wherein the homogenization speed in the process is about 3600 rpm;
(3) In the emulsification and homogenization process, 4g of sodium polyacryl dimethyl taurate is added, and after a thickening agent is added, the homogenization speed is increased by 4000rpm (the liquid level is reduced as much as possible, and the large-scale flow is ensured);
(4) Homogenizing for 5min, finding that a block remains on the homogenizer, scraping by using a silica gel plate/spoon handle, and homogenizing for 30s-1 min.
3. Stirring and cooling process
(1) After homogenization, the initial stirring speed is 260rpm (small vortex does not appear on the liquid surface) because the material body is thin;
(2) As the temperature decreases, the consistency increases, and the stirring speed gradually increases to about 300rpm (small eddies do not occur on the liquid surface);
(3) Cooling to about 40 ℃, respectively adding 2.4g of 1, 2-hexanediol and 6g of gamma-aminobutyric acid, and uniformly stirring;
(4) Constant weight. The essence emulsion of example 1 was obtained.
Example 2
The difference from example 1 is that: the amount of gamma-aminobutyric acid in the essence milk of example 2 was 3 parts, the corresponding deionized water was 79.2 parts, and other components and preparation methods were the same as those of example 1, and will not be described here again.
Example 3
The difference from example 1 is that: the amount of gamma-aminobutyric acid in the essence milk of example 3 was 4.5 parts, the corresponding deionized water was 77.7 parts, and other components and preparation methods were the same as in example 1, and will not be described here again.
Example 4
The difference from example 1 is that: the amount of gamma-aminobutyric acid in the essence milk of example 4 was 6 parts, the corresponding deionized water was 76.2 parts, and other components and preparation methods were the same as those of example 1, and will not be described here again.
Comparative example 1
The difference from example 1 is that: the essence emulsion of comparative example 1 used a non-liquid crystalline emulsifier, which is: the amount of the Heda A165 (INCI: glycerol stearate & PEG-100 stearate) and the non-liquid crystal emulsifier was 2 parts, and the other components and the preparation method were the same as in example 1, and will not be described again.
Comparative example 2
The difference from example 2 is that: the essence emulsion of comparative example 2 uses the same non-liquid crystal emulsifier as comparative example 1 in an amount of 2 parts, and other components and preparation methods are the same as example 2, and are not described here again.
Comparative example 3
The difference from example 3 is that: the essence emulsion of comparative example 3 uses the same non-liquid crystal emulsifier as comparative example 1 in an amount of 2 parts, and other components and preparation methods are the same as example 3, and are not described here again.
Comparative example 4
The difference from example 4 is that: the essence emulsion of comparative example 4 uses the same non-liquid crystal emulsifier as comparative example 1 in an amount of 2 parts, and other components and preparation methods are the same as example 4, and are not described here again.
The components of the essential milks of examples 1 to 4 and comparative examples 1 to 4 are shown in Table 1.
Table 1 components of the essential milks of the examples and comparative examples
Test example irritation evaluation
1. Patch test
1.1 definition and test principle
1.1.1 definitions
Patch testing is a method of primarily diagnosing delayed type (type iv) allergies, for determining whether a patient has contact allergies and evaluating the association between contact allergies and dermatitis occurrence.
1.1.2 principle of testing
After the local skin reappears the reaction process of the allergic contact dermatitis, i.e. after a small amount of allergen is directly contacted with the skin, whether mild dermatitis is locally induced is observed, thereby judging whether the skin is allergic to the allergen tested. The main mechanism of the patch test is type IV allergy, and the allergen used is usually a small molecular compound, namely an organic or inorganic substance with a relative molecular mass of less than 500000.
1.2 test method and procedure
Patients were informed of the purpose, precautions and adverse reactions of the patch test prior to testing. During the test, the backs of the patch tester were kept dry until the second interpretation. If the back of the test has hairs, the hairs should be shaved 1-2 days before the test, an electric shaver is used, and chemical dehairing is not used. After the test, the patient is informed not to swim, scratch the test site and avoid strenuous exercise, as the plaque tester may come off. To keep the back dry, no bathing, showering or unnecessary sweating movements are required. Exposure to sunlight was avoided during the test. The patients are informed that the back itching is hard, even the patients have pain or burning feeling, and should be contacted with doctors in time. If the patch begins to fall off during testing, the adhesive tape is used for reinforcement. When the spot tester is detached, the spot tester can be removed, and the time is recorded.
The back was cleaned with water and wiped dry. When the plaster is applied to a patient, the patient should be guided to straighten the sitting posture, and the shoulders bend back. The test core chamber should be located at the upper back or upper middle, optionally 2.5cm outside the mid-spinal reference point. The tester should be gently pressed from bottom to top to remove air from the core and then pressed with force to improve the adhesion of the tester. The top of each plaque cartridge was gently pressed to evenly distribute the allergen reagent in the chamber. After the tester is attached, marks are made on the top and bottom of the tester by using a fluorescent pen or a common marker pen. The tester may be reinforced with tape. The tester should be applied to the back for 48 hours and keep the site dry.
1.3 test results and analysis
As shown in table 2, it is clear from the patch test results that the patch test was not abnormal when the amount of gamma-aminobutyric acid added was <4.5% in 30 subjects, and the patch test results of the examples were superior to the patch test results of the corresponding proportions in each amount of gamma-aminobutyric acid, wherein the control was water.
Table 2 plaque test results
2. Stinging sensation test
The test was conducted by referring to the method of "evaluation method for suitability of a face-sensitive skin cosmetic" (reference: ma Li, yimei, cheng Ying, etc., evaluation method for suitability of a face-sensitive skin cosmetic, research on the method of suitability of a face-sensitive skin cosmetic, journal of dermatology, incorporated by chinese, western medicine, volume 17, phase 1, 2018).
And selecting a subject with uncomfortable feeling on gamma aminobutyric acid for testing, and screening for one week after passing the screening. The total number of enrolled subjects was 35. A1 mL sample was placed in the subject's bilateral nasolabial folds, using the comparative example on one side, while the example was used on the other side. Stinging sensation was assessed separately. The subjects were evaluated for the degree of discomfort of itching, stinging, burning sensation at the test site, stinging criteria and scores as follows:
no sensation was given to 0, little tingling, strong tingling, mild tingling, and intense tingling to 3 and 4.
Stinging score= (0 min+1min+5min comparative example side stinging score) (0 min+1min+5min example side stinging score).
Statistical analysis was performed using the Wilcoxon signed-order test method, with a level set of a=0.05 test mean to the beneficial direction, and test result p <0.05, indicating validity.
Specific results of the stinging scores of examples 1 to 4 and comparative examples 1 to 4 are shown in Table 3.
TABLE 3 stinging score for each time point for examples 1-4 and comparative examples 1-4
As can be seen from the data of examples 1 to 4 and comparative examples 1 to 4 in Table 3, the stinging sensation was enhanced as the amount of gamma aminobutyric acid added was increased; in the emulsifying system, liquid crystal emulsifier and non-liquid crystal emulsifier are added in equal quantity, and along with the increase of the addition amount of gamma-aminobutyric acid, the stinging feeling of the emulsifying system containing the liquid crystal emulsifier is obviously weaker than that of the non-liquid crystal emulsifying system, and particularly, the addition amount of the liquid crystal emulsifier can be increased to 4.5%, so that the balance between the efficacy and stinging feeling of the gamma-aminobutyric acid is solved to a great extent.
In conclusion, the liquid crystal emulsifier is combined with the gamma aminobutyric acid, so that the instant discomfort, especially stinging sensation brought by the high-content gamma aminobutyric acid in an emulsifying system can be effectively relieved, the balance between the efficacy of gamma aminobutyric acid and stinging sensation is solved to a great extent, and the purchase intention of consumers is improved.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present application, and not for limiting the same; although the present application has been described in detail with reference to the foregoing embodiments, it should be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present application.
Furthermore, those skilled in the art will appreciate that while some embodiments herein include some features but not others included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the present application and form different embodiments. For example, in the claims below, any of the claimed embodiments may be used in any combination. The information disclosed in this background section is only for enhancement of understanding of the general background of the application and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Claims (10)
1. A composition for improving the irritation associated with gamma-aminobutyric acid, comprising, per 100 parts by weight: 1-6 parts of gamma-aminobutyric acid and 1-4 parts of liquid crystal emulsifier, wherein the liquid crystal emulsifier comprises the following components in parts by weight: arachidyl alcohol, behenyl alcohol and arachidyl alcohol glucoside, wherein the weight ratio of the arachidyl alcohol to the behenyl alcohol to the arachidyl alcohol glucoside is (50-60): (25-35): (10-20), the balance being water.
2. The composition for improving the irritation associated with gamma-aminobutyric acid according to claim 1, wherein the composition further comprises, per 100 parts by weight: 5-10 parts of grease;
the oil is selected from isononyl isononanoate, glycerol tri (ethyl hexanoate), polydimethylsiloxane and Begonia seed oil.
3. The composition for improving the irritation associated with gamma-aminobutyric acid according to claim 2, wherein the oil or fat is selected from any one or a combination of two of isononyl isononanoate and tri (ethylhexanoic acid) ester.
4. The composition for improving the irritation associated with gamma-aminobutyric acid according to claim 1, wherein the composition further comprises, per 100 parts by weight: 0.3 to 1 part of fatty alcohol and 0.5 to 2 parts of thickener;
the fatty alcohol is selected from any one or more of cetostearyl alcohol, cetyl alcohol, stearyl alcohol and behenyl alcohol;
the thickener is selected from one or more of xanthan gum, sodium polyacryl dimethyl taurate, sodium acrylate/sodium acryloyl dimethyl taurate copolymer, polyacrylate crosslinked polymer-6 and carbomer.
5. The composition for improving the irritation associated with gamma-aminobutyric acid according to claim 4, wherein the fatty alcohol is selected from cetostearyl alcohol and behenyl alcohol;
the thickener is selected from xanthan gum and sodium polyacryl dimethyl taurate.
6. The composition for improving the irritation associated with gamma-aminobutyric acid according to claim 1, wherein the composition further comprises, per 100 parts by weight: 3.5 to 12 parts of preservative and 1 to 3 parts of humectant;
the preservative comprises: any one or a combination of a plurality of 1, 3-butanediol, p-hydroxyacetophenone and 1, 2-hexanediol;
the moisturizer comprises: glycerol.
7. A method for preparing a composition for improving the irritation of gamma-aminobutyric acid, comprising:
mixing 1, 3-butanediol, glycerol, xanthan gum, p-hydroxyacetophenone and water, heating, dissolving, and maintaining the temperature to obtain a water phase;
mixing oil, a liquid crystal emulsifier and fatty alcohol, heating, dissolving and preserving heat to obtain an oil phase;
adding the oil phase into the water phase, adding sodium polyacryl dimethyl taurate, and emulsifying and homogenizing;
and after the emulsification and homogenization are finished, stirring and cooling, respectively adding 1, 2-hexanediol and gamma-aminobutyric acid, and uniformly stirring to obtain the composition for improving the irritation of the gamma-aminobutyric acid.
8. The method for producing a composition for improving the irritation associated with gamma-aminobutyric acid according to claim 7, wherein the emulsifying homogenization speed is 3600 to 4500rpm; the time for emulsification and homogenization is 5-8 min; the stirring and cooling speed is 260-300 rpm.
9. Use of a composition for improving the irritation associated with gamma-aminobutyric acid according to any one of claims 1 to 6 for the preparation of a skin care product.
10. A skin care product comprising the composition for improving the irritation of gamma-aminobutyric acid according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310205916.XA CN116059124A (en) | 2023-03-06 | 2023-03-06 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310205916.XA CN116059124A (en) | 2023-03-06 | 2023-03-06 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116059124A true CN116059124A (en) | 2023-05-05 |
Family
ID=86176942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310205916.XA Pending CN116059124A (en) | 2023-03-06 | 2023-03-06 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116059124A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020076874A (en) * | 2001-03-31 | 2002-10-11 | 엔프라니 주식회사 | Cosmetic composition for lowering stimulation of the skin and enhancing moisturization of the skin |
| CN108451837A (en) * | 2018-06-28 | 2018-08-28 | 武汉百思凯瑞生物科技有限公司 | A kind of whitening liquid-crystal composition and its preparation method and application |
| CN108938439A (en) * | 2018-09-28 | 2018-12-07 | 广州市科能化妆品科研有限公司 | Liquid crystal type emulsification composition and its preparation method and application |
| CN110368323A (en) * | 2019-08-05 | 2019-10-25 | 广州市玉鑫化妆品有限公司 | A kind of composite skin care product and its preparation method and application containing liquid crystal emulsifier |
| CN111297699A (en) * | 2020-01-14 | 2020-06-19 | 名臣健康用品股份有限公司 | Moisturizing body lotion with good liquid crystal structure and preparation method thereof |
| CN114732743A (en) * | 2022-02-21 | 2022-07-12 | 莹特丽科技（苏州工业园区）有限公司 | Moisturizing and anti-wrinkle face cream with lamellar liquid crystal structure and preparation method thereof |
-
2023
- 2023-03-06 CN CN202310205916.XA patent/CN116059124A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020076874A (en) * | 2001-03-31 | 2002-10-11 | 엔프라니 주식회사 | Cosmetic composition for lowering stimulation of the skin and enhancing moisturization of the skin |
| CN108451837A (en) * | 2018-06-28 | 2018-08-28 | 武汉百思凯瑞生物科技有限公司 | A kind of whitening liquid-crystal composition and its preparation method and application |
| CN108938439A (en) * | 2018-09-28 | 2018-12-07 | 广州市科能化妆品科研有限公司 | Liquid crystal type emulsification composition and its preparation method and application |
| CN110368323A (en) * | 2019-08-05 | 2019-10-25 | 广州市玉鑫化妆品有限公司 | A kind of composite skin care product and its preparation method and application containing liquid crystal emulsifier |
| CN111297699A (en) * | 2020-01-14 | 2020-06-19 | 名臣健康用品股份有限公司 | Moisturizing body lotion with good liquid crystal structure and preparation method thereof |
| CN114732743A (en) * | 2022-02-21 | 2022-07-12 | 莹特丽科技（苏州工业园区）有限公司 | Moisturizing and anti-wrinkle face cream with lamellar liquid crystal structure and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109846757B (en) | Sebum biomimetic composition and cosmetic containing same | |
| DE102004028302B4 (en) | Stimulating the synthesis and activity of an isoform of lysyl oxidase-like LOXL to stimulate the formation of elastic fibers | |
| CN108938439B (en) | Liquid crystal type emulsified composition and preparation method and application thereof | |
| KR101500191B1 (en) | Skin care compositions and method for manufacturing the same | |
| JPS61271205A (en) | Skin cosmetic | |
| CN103622885B (en) | There is skin care compositions, preparation and preparation method thereof that anti-acne prints effect | |
| CN112370408B (en) | Composition with high moisturizing effect and application thereof in cosmetics | |
| CN116059124A (en) | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof | |
| US20130345315A1 (en) | Water-releasing cosmetic composition | |
| JP2007008912A (en) | Method of cosmetic treatment for maintaining homeostasis of rhythm of life | |
| CN114632024A (en) | Refreshing and moisturizing composition containing hydrogenated starch hydrolysate | |
| JP2005289995A (en) | Oil/water type cosmetic composition manufactured using polyglyceryl-3-methylglucose distearate | |
| CN115463040B (en) | Water emulsion double-layer quick-time moisturizing skin care product and preparation method thereof | |
| RU2432152C2 (en) | Application of alkyloxazolidinone as moisturising cosmetic agent and method of skin moisturising | |
| JP2001278768A (en) | Skin care preparation | |
| CN115400041B (en) | Cosmetic composition with alpha gel structure and preparation method thereof | |
| CN114668682B (en) | Moisturizing and skin-brightening composition and application thereof | |
| RU2252015C1 (en) | Preparation for biological skin rejuvenation | |
| US11975084B2 (en) | Composition for application to a surface of skin of a user | |
| CN114948769A (en) | Emulsified smearing mask with relieving and repairing effects | |
| CN110141526B (en) | Moisturizing and anti-wrinkle emulsion and preparation method thereof | |
| CN117017873A (en) | Sun-screening composition containing peony active ingredient and preparation method and application thereof | |
| JP2000178118A (en) | Humectant, skin cosmetic and bathing agent | |
| KR20230109079A (en) | Liquid crystal emulsion having an excellent effect on skin barrier improvement and skin moisturizing | |
| CN111110606A (en) | Skin-moistening composition, preparation method thereof and skin-moistening emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |